Read by QxMD icon Read

high dose cytarabine t(15;17)

Aki Saito, Yasuhiro Okamoto, Yuko Seki, Manaka Matsunaga, Shunsuke Nakagawa, Yuichi Kodama, Takuro Nishikawa, Takayuki Tanabe, Yoshifumi Kawano
An 8-year-old boy developed anorexia, fatigue, and fever. Laboratory examination revealed a high white blood cell (WBC) count of 145×10/μL with 97.5% abnormal promyelocytic cells that contained Auer bodies. Faggot cells were seen. He was diagnosed with acute promyelocytic leukemia. Later, a chromosome analysis showed 46,XY,t(15;17)(q22;q12). Promyelocytic Leukemia-retinoic acid receptor α-fused gene and chimeric mRNA were confirmed by fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction, respectively...
August 2016: Journal of Pediatric Hematology/oncology
Dong Lin, Chunlin Zhou, Hui Wei, Bingcheng Liu, Ying Wang, Kaiqi Liu, Wei Li, Benfa Gong, Jinyu Wang, Shuning Wei, Guangji Zhang, Xingli Zhao, Yan Li, Yuntao Liu, Xiaoyuan Gong, Mingyuan Sun, Yuan Lu, Yingchang Mi, Jianxiang Wang
OBJECTIVE: To investigate the characteristics and the short- or long-term treatment outcomes of the adult patients with acute myeloid leukemia (AML) in China. METHODS: From 1999 to 2010, 822 adult cases with AML were enrolled, diagnosed and classified by the FAB and WHO criteria, respectively. The treatment outcomes and prognostic factors were analyzed retrospectively. RESULTS: In all patients with a median age of 38.5(15-83) years, acute monoblastic and monocytic leukemia (M5), AML with t(15;17)/PML-RARα (APL) and AML with t(8;21)/AML1-ETO(M2b) were the most common subtypes, accounting for 29...
December 2014: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Mohamad Khawandanah, Bradley Gehrs, Shibo Li, Jennifer Holter Chakrabarty, Mohamad Cherry
Background. We hereby describe what we believe to be the first reported case of t (14; 15) (q32; q13) associated with acute myeloid leukemia (AML). Methods. PubMed, Embase, and OVID search engines were used to review the related literature and similar published cases. Case. A47-year-old female presented in December 2011 with AML (acute myelomonocytic leukemia) with normal cytogenetics; molecular testing revealed FLT-3 internal tandem duplication (ITD) mutation, while no mutations involving FLT3 D385/I836, NPM1 exon 12, or KIT exons 8 and 17 were detected...
2014: Case Reports in Genetics
Rajni Sinha, Pareen J Shenoy, Nassoma King, Mary Jo Lechowicz, Kevin Bumpers, Donald Hutcherson, Martha Arellano, Amelia Langston, Jonathan Kaufman, Leonard T Heffner, Edmund K Waller, Ajay Nooka, Christopher R Flowers, Sagar Lonial
BACKGROUND: For Hodgkin lymphoma (HL) patients with refractory or relapsed (R/R) disease after primary therapy, the standard of care is a salvage regimen followed by autologous stem cell transplant (ASCT). However, patients who fail to respond to a salvage regimen have limited options. Our phase I study of cytarabine combined with fixed doses of vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for patients with R/R lymphoma showed an overall response rate (ORR) of 33%. PATIENTS AND METHODS: To further examine the effectiveness of VTEPA, we conducted a retrospective review of 30 cases of R/R HL who received a salvage combination of VTEPA...
December 2013: Clinical Lymphoma, Myeloma & Leukemia
Martha Arellano, Elliott Winton, Lin Pan, Lisa Lima, Mourad Tighiouart, Kapil Bhalla, Leonard T Heffner, Jessica Neely, Donald Hutcherson, Morgan McLemore, Amelia Langston, H Jean Khoury
BACKGROUND: High-dose cytarabine (HiDAC) is safe and very effective in younger patients with acute myeloid leukemia (AML), but it generally is not well tolerated in the elderly. METHODS: The authors explored the safety and tolerability of a modified HiDAC induction regimen consisting of 6 daily doses of cytarabine at 2 g/m(2) in combination with 3 daily doses of daunorubicin at 45 mg/m(2) in 59 consecutive patients aged >60 years who had de novo AML diagnosed between July 1996 and February 2005...
January 15, 2012: Cancer
H Syrjälä, P Ohtonen, U Kinnunen, R Räty, E Elonen, T Nousiainen, E Jantunen, K Remes, M Itälä-Remes, R Silvennoinen, P Koistinen
The purpose of this study was to assess the frequency of blood stream infections (BSIs) during neutropenia in different cycles of intensive chemotherapy treatment in acute myeloid leukemia (AML). The register data of 327 consecutive patients aged 16-66 years having de novo AML between September 1992 and December 2001 were prospectively gathered in five Finnish tertiary care leukemia centers. The patients had not received fluoroquinolone prophylaxis. Reported BSI rates were compared during neutropenia in four chemotherapy treatment cycles (C)...
October 2010: European Journal of Clinical Microbiology & Infectious Diseases
Gesche Tallen, Richard Ratei, Georg Mann, Gertjan Kaspers, Felix Niggli, Alexandr Karachunsky, Wolfram Ebell, Gabriele Escherich, Martin Schrappe, Thomas Klingebiel, Ruediger Fengler, Günter Henze, Arend von Stackelberg
PURPOSE: The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort. PATIENTS AND METHODS: Five hundred twenty-five patients stratified into risk groups A (early bone marrow [BM] relapses), B (late BM relapses), and C (isolated extramedullary relapses) received alternating short-course intensive polychemotherapy (in blocks R1, R2, or R3) and cranial/craniospinal irradiation followed by maintenance therapy...
May 10, 2010: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Bhawna Sirohi, Ray Powles, Seema Singhal, Katy Smith, Robin L Jones, Radovan Saso, Samar Kulkarni, Jennifer Treleaven, G John Swansbury, Mike Potter, Gareth Morgan, Jayesh Mehta
One-hundred-twenty consecutive adult patients aged 15-69 years (median 40) with acute myeloid leukemia (AML) excluding t(15;17) received induction therapy comprising idarubicin, high-dose cytarabine and etoposide. Planned post-induction treatment included two courses of moderate-intensity consolidation therapy followed by stem cell transplantation. 11 patients (9%) died during induction therapy. The complete remission (CR) rate with a single cycle of induction therapy was 71%. The overall CR rate, after salvage chemotherapy but excluding allogeneic transplantation for primary refractory disease, was 82%...
December 2008: Leukemia & Lymphoma
Krzysztof Mrózek, Clara D Bloomfield
Acquired genetic alterations such as balanced and unbalanced chromosome aberrations and submicroscopic gene mutations and changes in gene expression strongly affect pretreatment features and prognosis of adults with acute myeloid leukemia (AML). The most frequent chromosome/molecular rearrangements, that is, t(8;21)(q22;q22)/RUNX1-RUNX1T1 and inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 characteristic of core-binding factor (CBF) AML and t(15;17)(q22;q12-21)/PML-RARA characteristic of acute promyelocytic leukemia (APL), confer favorable clinical outcome when patients receive optimal treatment, that is, regimens that include high-dose cytarabine for CBF AML and all-trans-retinoic acid and/or arsenic trioxide for APL...
2008: Journal of the National Cancer Institute. Monographs
Markus Schaich, Richard F Schlenk, Haifa K Al-Ali, Hartmut Döhner, Arnold Ganser, Gerhard Heil, Thomas Illmer, Rainer Krahl, Jürgen Krauter, Cristina Sauerland, Thomas Büchner, Gerhard Ehninger
BACKGROUND AND OBJECTIVES: Trisomy 8 (+8) is among the commonest genetic aberrations seen in acute myeloid leukemia (AML). However, the prognostic significance of this aberration and the best consolidation strategy for patients with it are still not resolved. Additional prognostic indicators are needed to further classify these patients and determine their appropriate management. DESIGN AND METHODS: Individual patient data-based meta-analysis was performed on 131 patients (median age 50 (18-60) years) with +8 as a sole aberration or +8 with one additional aberration treated between 1993 and 2002 in eight prospective German AML treatment trials...
June 2007: Haematologica
Adham Zayed, Stephen Couban, Ormille Hayne, Nebojsa Sparavalo, Allam Shawwa, Irene Sadek, Wenda Greer
Acute promyelocytic leukemia (APL) is characterized by increased promyelocytes in the marrow that harbor a t(15;17) and promyelocyte leukemia (PML)/RARalpha fusion gene. The oncogenic gene product is believed to act through disruption of the transcription-modulating function of RARalpha. Differentiation of promyelocytes and remission is achieved with all transretinoic acid (ATRA) therapy usually in combination with chemotherapy. This report describes a patient with the t(15;17) who did not respond typically to ATRA and IDAC induction chemotherapy, although achieved and remains in complete remission five years following induction and one consolidation with high dose cytarabine (HIDAC)...
March 2007: Leukemia & Lymphoma
M N Dufourg, J Landman-Parker, M F Auclerc, C Schmitt, Y Perel, G Michel, P Levy, G Couillault, V Gandemer, M D Tabone, F Demeocq, J P Vannier, T Leblanc, G Leverger, A Baruchel
The objective of the study was to assess acute neurotoxicity associated with triple intrathecal therapy (TIT)+/-high-dose methotrexate (HD MTX) in children with acute lymphoblastic leukemia (ALL). 1395 children were enrolled on FRALLE 93 protocol from 1993 to 1999. Lower-risk group (LR, n=182) were randomized to weekly low-dose MTX at 25 mg/m(2)/week (LD MTX, n=81) or HD MTX at 1.5 g/m(2)/2 weeks x 6 (n=77). Intermediate-risk group (IR, n=672) were randomized to LD MTX (n=290) or HD MTX at 8 g/m(2)/2 weeks x 4 (n=316)...
February 2007: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
T Kuittinen, M Husso-Saastamoinen, P Sipola, O Vuolteenaho, M Ala-Kopsala, T Nousiainen, E Jantunen, J Hartikainen
Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY. We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m2/day as a part of BEAC high-dose therapy (HDT). Magnetic resonance imaging (MRI) and plasma natriuretic peptide (NT-proBNP, NT-proANP) measurements were performed prior to HDT (d-7) and just after completing HDT (d-2). After the high-dose CY left atrial end-systolic area increased from 15...
December 2005: Bone Marrow Transplantation
I M Hann, D K W Webb, B E S Gibson, C J Harrison
The modern approach to therapy for acute myeloid leukaemia (AML) in children began in the late 80's and in the MRC series led to a 30% improvement in survival, up to levels of about 50%. Since 1995 the most recent trial AML 12 has taken those figures to two thirds event free survival and similar overall survival. Resistant disease rates remain at 4% overall but the death rate in complete remission has fallen from 11% to 6% despite increasing intensity of therapy, and due to advances in supportive care including nutrition and antibiotics/antifungals...
2004: Annals of Hematology
N Kröger, L Damon, A R Zander, H Wandt, G Derigs, P Ferrante, T Demirer, G Rosti, , et al.
The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median follow-up of 57 months (range 10-125), three cases of secondary AML (sAML) were observed, resulting in a cumulative incidence of 0...
December 2003: Bone Marrow Transplantation
Keun-Wook Lee, In Sil Choi, Eun Youn Roh, Dae-Young Kim, Tak Yun, Dong Soon Lee, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim
Clinical features and treatment outcome of 31 patients over 16 years of age with t(8;21) acute myeloid leukemia (AML) were compared with 60 patients without t(8;21). Among 31 patients with t(8;21), 15 patients were classified as AML-M2 and 11 and 5 patients as AML-M4 and M1, respectively. Of these patients, 28 patients (90.3%) achieved complete remission and 22 patients received consolidative treatment: intermediate-dose cytarabine (IDAC) 11, high-dose cytarabine (HDAC) 6, and allogeneic bone marrow transplantation (BMT) 5...
April 2004: Annals of Hematology
Fan-Yi Meng, Wei-Yang Zheng, Xiao-Li Liu, Lan-Lin Song, Bing Xu, Yu Zhang, Fen Huang
BACKGROUND & OBJECTIVE: Glivec was approved by Food & Drug Administration (FDA) in May 2001 as a gene target drug for treatment of chronic myeloid leukemia (CML) and showed a good curative effect for patients with chronic myeloid leukemia in chronic phase. But its effectiveness was poor in patients with CML blast phase treated with Glivec alone. Glivec was reported having synergetic effect with other chemical agents in vitro, but there is few report in clinical combined application. In this paper, we analyzed effectiveness of Glivec in combination with homoharringtonine (HHT) and cytarabine (Ara-C) for patients with Ph chromosome positive acute leukemia (Ph(+)-AL), and investigated patients' tolerance to side effects of this trial...
August 2003: Ai Zheng, Aizheng, Chinese Journal of Cancer
M Cotter, H Enright
We report a novel t(15;17)(q15;q11) translocation in acute myeloid leukaemia (AML M4) which was not associated with PML/RARalpha rearrangement or with acute promyelocytic leukaemia (APL) morphology. The leukaemia behaved in refractory fashion, with 70% blasts in the bone marrow after the first course of chemotherapy. In view of the refractory behaviour of the leukaemia, the patient was treated with high dose chemotherapy and autologous stem cell rescue. The patient is alive and well 22 months post-autologous stem cell transplant...
August 2003: Clinical and Laboratory Haematology
W K Hofmann, G Seipelt, S Langenhan, R Reutzel, D Schott, O Schoeffski, H J Illiger, F Hartmann, L Balleisen, A Franke, F Fiedler, C Huber, H Rasche, L Bergmann, A Ganser, C Pott, R Pasold, C Rudolph, O G Ottmann, N Gökbuget, D Hoelzer
In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections. However, the optimal timing of G-CSF administration after chemotherapy is not known. In a prospective randomized multi-center study, adult ALL patients were treated with high-dose ARA-C [HDAC, 3 g/m(2) bid (1 g/m(2) bid for T-ALL) days 1-4] and mitoxantrone (MI 10 mg/m(2) days 3-5). They were randomized to receive recombinant human G-CSF (Lenograstim) 263 micro g/day SC starting either from day 12 (Group 1) or day 17 (Group 2)...
October 2002: Annals of Hematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"